Jim Baranski, Government Director at Lung Most cancers Basis of America, shared on LinkedIn:
“A examine out of Stony Brook Most cancers Heart this week introduced that one among their groups engineered a remedy that mixes a pure tumor-suppressing molecule with a typical chemotherapy drug, designed particularly to cease non-small cell lung most cancers from creating drug resistance.
Of their lab mannequin, tumors shrank by greater than 95%. That is early, preclinical work.
Virtually each remedy now saving lives went via this precise stage first: promising, unproven, and in want of somebody prepared to fund the subsequent step.
That’s the hole Lung Most cancers Basis of America exists to fill. As of this 12 months, our researchers have produced a 13x ROI.
Science wants science, constructing on itself to maneuver ahead.
And each thought is unproven – till a researcher units out in the hunt for that eureka second.
What’s one thing you would like extra individuals knew about lung most cancers analysis?”
Stony Brook Cancer Center Study Shows Promise of New Approach to Treat Lung Cancer
Different articles about lung cancer on OncoDaily.
